Recruiting Liver Cancer Studies in Detroit
National Liver Cancer Screening Trial
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or pati...
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic...
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor...
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unrese...
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CC...
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microsphere...
About Liver Cancer Clinical Trials in Detroit
Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.
There are currently 6 liver cancer clinical trials recruiting participants in Detroit, MICHIGAN. These studies are seeking a combined 6,758 participants. Research is being sponsored by University of Texas Southwestern Medical Center, AbbVie, TransThera Sciences (Nanjing), Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Liver Cancer Clinical Trials in Detroit — FAQ
Are there liver cancer clinical trials in Detroit?
Yes, there are 6 liver cancer clinical trials currently recruiting in Detroit, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Detroit?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.
Are clinical trials in Detroit free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.
What liver cancer treatments are being tested?
The 6 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.
Data updated March 2, 2026 from ClinicalTrials.gov